These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32727756)

  • 1. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
    Shimura Y; Suga Y; Itai S; Iwamoto H; Takezawa Y; Yaegashi H; Izumi K; Shimada T; Sai Y; Matsushita R; Mizokami A
    Anticancer Res; 2020 Aug; 40(8):4291-4297. PubMed ID: 32727756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
    Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
    Yamashita T; Shiota M; Machidori A; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Cancer Invest; 2021 Mar; 39(3):251-256. PubMed ID: 33393849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
    Byeon S; Kim H; Jeon HG; Seo SI; Jeon SS; Lee HM; Lee SI; Park SH
    BMC Cancer; 2021 Nov; 21(1):1281. PubMed ID: 34839812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
    Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
    Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer.
    Kim HS; Lee JY; Lee SJ; Lim HY; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Park SH
    BMC Urol; 2017 Aug; 17(1):63. PubMed ID: 28830482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Lavoie JM; Zou K; Khalaf D; Eigl BJ; Kollmannsberger CK; Vergidis J; Noonan K; Zulfiqar M; Finch D; Chi KN
    Prostate; 2019 Feb; 79(3):281-287. PubMed ID: 30370697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer.
    Ang JW; Tan MH; Tay MH; Toh CK; Ng QS; Kanesvaran R
    Ann Acad Med Singap; 2017 May; 46(5):195-201. PubMed ID: 28600580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
    Mangir N; Türkeri L
    Actas Urol Esp; 2014 Oct; 38(8):515-22. PubMed ID: 24646918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
    Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
    Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
    Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
    Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
    BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):561-566. PubMed ID: 31115605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
    Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
    Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
    Courtney KD; Manola JB; Elfiky AA; Ross R; Oh WK; Yap JT; Van den Abbeele AD; Ryan CW; Beer TM; Loda M; Priolo C; Kantoff P; Taplin ME
    Clin Genitourin Cancer; 2015 Apr; 13(2):113-23. PubMed ID: 25450031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer.
    Yoon SE; Kim Y; Cho J; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Lee SJ; Park SH
    BMC Urol; 2019 May; 19(1):30. PubMed ID: 31053137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
    J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.